Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ: NUVB), completed a sale of 36,750 shares of the company’s Class A Common Stock on April 17, 2026, generating proceeds of $184,279. The shares were sold at prices ranging from $5.00 to $5.05 per share under a pre-arranged 10b5-1 trading plan that was established on December 4, 2025.
The sale followed Ms. Wentworth’s exercise of stock options for the same number of shares - 36,750 Class A Common Stock shares - at an exercise price of $2.93 per share, for a total exercise cost of $107,677. After completing both the option exercise and the sale, Ms. Wentworth directly holds 53,000 shares of Nuvation Bio Class A Common Stock and retains 215,250 stock options.
Vesting terms and option life
The disclosed options vest over time. A quarter of the options vested on the first anniversary of August 29, 2022, with the balance vesting monthly over the next 36 months, subject to continuous service. The outstanding options carry an expiration date of August 28, 2032.
Market context and valuation note
The insider filing arrives as Nuvation Bio shares have risen substantially over the last year, delivering a 158.59% return. At the time of the filing the stock was trading at $5.11. Analysis available through InvestingPro is cited as indicating the stock appears undervalued relative to its Fair Value, with investors able to access more detailed coverage via the platform’s Pro Research Report.
Recent corporate developments cited in filings
The company has also reported several strategic developments that may factor into investor assessments. Nuvation Bio announced an amended license agreement with Daiichi Sankyo that grants Nuvation exclusive global development and commercialization rights for safusidenib, including rights in Japan. The disclosure notes this amendment follows the structure of the original 2020 agreement with AnHeart, under which Daiichi Sankyo had retained rights in Japan.
Separately, the European Medicines Agency has validated the Marketing Authorization Application for taletrectinib, an application directed at treating advanced ROS1-positive non-small cell lung cancer. That application will proceed under the EMA’s standard review timeline, and the company plans additional filings for the U.K., Canada, and other regions.
Analyst actions referenced
In connection with these developments, several brokerages have updated their views. Truist Securities reaffirmed a Buy rating with a $12.00 price target following meetings with company management. RBC Capital raised its price target to $20.00 from $13.00 while maintaining an Outperform rating, citing potential revenue from the glioma market. H.C. Wainwright reiterated a Buy rating with a $17.00 price target in light of the regulatory developments in Europe. These analyst moves are noted in the company disclosures.
What the filings show
The filings provide a snapshot of insider liquidity activity: the sale was executed under a pre-established trading plan, and the sale followed concurrent option exercise. The option schedule and expiration date are disclosed, and broader corporate developments and analyst reactions are presented in the company updates referenced in the same reports.